U.S. Antitrust Investigation of Generics to Look into Two Dozen Drugs - Bloomberg

November 3, 2016 2:11 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

(Updated - November 3, 2016 2:23 PM EDT)

U.S. prosecutors are "bearing down" on generic pharma companies in a sweeping criminal investigation into suspected price collusion, according to Bloomberg. The antitrust investigation by the DOJ spans more than a dozen companies and two dozen drugs, sources told the news service. A grand jury probe is examining some executives and the first charges could emerge by the end of the year.

Companies mentioned in the report include Mylan (NASDAQ: MYL), Allergan (NYSE: AGN) and Teva Pharma (NYSE: TEVA), Lannett (NYSE: LCI), Impax Laboratories (NASDAQ: IPXL), Covis, Sun Pharma, Mayne, Endo (NASDAQ: ENDP), and Taro Pharma (NYSE: TARO).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, ETFs, Hot Corp. News, Litigation, Trader Talk

Add Your Comment